anti-B7-H3 antibody-drug conjugate YL201

{
  "id": "MLC-T-ONC-010136",
  "term": "anti-B7-H3 antibody-drug conjugate YL201",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically conjugated to an as of yet undisclosed topoisomerase-1 inhibitor via a tumor protease-cleavable linker, with potential antineoplastic activity. Upon administration of anti-B7-H3 ADC YL201, the antibody moiety targets and binds to B7-H3-expressing tumor cells. Upon binding, internalization and linker cleavage, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing B7-H3. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation, and its overexpression plays a key role in tumor cell invasion and metastasis.",
  "synonyms": [
    "ADC YL201",
    "anti-B7-H3 ADC YL201"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-b7-h3-antibody-drug-conjugate-yl201/"
}